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Abstract. Angiosarcoma is a rare and highly aggressive
tumor of endothelial origin. The molecular mechanisms
driving angiosarcoma growth have not been fully elucidated,
although autocrine stimulation by vascular endothelial
growth factor (VEGF) secretion may play a role in the
pathogenesis of this tumor. We identified a patient with a very
rare form of angiosarcoma arising from the retroperitoneum.
Immunohistochemical analysis demonstrated widespread up-
regulation of the hypoxic response pathway as a mechanism
of enhanced VEGF expression. Disordered regulation of the
hypoxic response pathway can result in the expression of
factors such as VEGF and erythropoietin, which may
promote autocrine tumor growth in angiosarcoma.
Angiosarcoma is a rare sarcoma of purely endothelial
origin, which has seldom been reported to arise in the
retroperitoneum or kidney (1-4). These tumors are
composed of poorly-differentiated endothelial cells, which
form diffuse tubular networks, that are highly vascular and
often hemorrhagic. Retroperitoneal angiosarcoma tends to
be aggressive and rapidly fatal if not amenable to primary
surgical management. Angiosarcomas, as endothelial cells,
express the receptors for vascular endothelial growth factor
(VEGF), flt-1 (VEGF-R1) and KDR/flk-1 (VEGF-R2).
Previous studies have demonstrated that these tumors can
also produce VEGF, which provides a potential mechanism
of autocrine-mediated growth stimulation (5,6). VEGF is
primarily expressed and secreted from cells of epithelial
origin, but the mechanism promoting VEGF expression in
these tumors has not been identified.
A potential mechanism for the enhanced expression of
VEGF is the activation of the hypoxic response pathway. The
cellular hypoxic response includes the transcriptional
activation of genes involved in angiogenesis, erythropoiesis
and anaerobic metabolism. This response is mediated by the
transcription factors HIF1· (hypoxia inducible factor) and
HIF2·, which activate the hypoxic response by promoting the
transcription of a large number of genes involved in
angiogenesis (VEGF, angiopoietin 1 and angiopoietin 2),
oxygen delivery (erythropoietin) and glycolysis (glut-1, lactate
dehydrogenase, phosphofructokinase, carbonic anhydrases)
(7-9). Under normal oxygen tension, HIF (this term
designates either HIF1· or HIF2·) is rapidly targeted for
proteasomal degradation through an interaction with the von
Hippel-Lindau (VHL) tumor suppressor (10-12). When
oxygen levels become limiting, this interaction is disrupted
and HIF accumulates in local regions of hypoxia. HIF can
also be found at high levels in tumors independent of hypoxic
stimulation (13). Clear cell renal cell carcinomas associated
with VHL mutations demonstrate HIF expression, as well as
expression of HIF target genes, including VEGF (14). HIF
regulation can also be mediated by transcriptional activation
via loss of the TSC2 tumor suppressor gene, which causes
HIF accumulation as well as VEGF accumulation as a result
of loss of inhibition of mTOR (15). Additionally, HIF
expression may be modulated by the PTEN/AKT pathway
(16). Although many potential mechanisms of HIF activation
have been postulated, tumors which express HIF and VEGF
have been demonstrated to correlate with both tumor
vascularity and growth rate (17).
We report an analysis of one patient presenting with a
primary retroperitoneal angiosarcoma, identifying constitutive
HIF overexpression in this tumor as a mechanism for aberrant
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VEGF expression. Furthermore, HIF expression promotes
transcription of other growth factors including erythropoietin,
suggesting multiple modes of autocrine-stimulated tumor
growth.
Materials and Methods
Immunohistochemistry. The tumor tissue was fixed immediately
following resection and paraffin embedded according to routine
clinical protocols. Immunohistochemical stains were performed as
described previously (18). Primary antibodies included HIF1·
(Novus), HIF2· (Novus), VEGF (NeoMarkers), VEGFR2 (Dako),
Flk1 (Novus), erythropoietin (Genzyme) and carbonic anhydrase IX
(Santa Cruz). Secondary antibody detection was performed with
appropriate biotin-conjugated antibodies (Vector Laboratories).
Detection was enhanced with ABC enhancement kit (Vectashield)
and detected with DAB reagent (Vector Laboratories). Appropriate
positive and negative controls were performed (data not shown).
Results
A 49-year-old male with a history of cadaveric renal transplant
for glomerulonephritis-related renal failure was found to have
a mass in the lower pole of the native left kidney without
associated lymphadenopathy. A radical nephrectomy was
performed, which revealed a primary retroperitoneal
angiosarcoma with invasion and replacement of the native left
kidney. We performed immunohistochemistry on this tumor
specimen and found high levels of expression of both VEGF
and the VEGF receptor, flk-1 (Figure 1, A and B). 
Tumor sections within this angiosarcoma demonstrated
high level expression of other genes transcriptionally
activated by the hypoxic response pathway, including
carbonic anhydrase IX and erythropoietin (Figure 1, C and
D), not normally expressed in endothelial cells. Endothelial
cells in general and cells from this angiosarcoma, however,
do express the erythropoietin receptor (data not shown),
suggesting another autocrine mechanism supporting the
proliferation of this tumor. Finally, we observed that both
HIF1· and HIF2· were expressed at high levels throughout
the tumor, but limited to the tumor cells and sparing the
surrounding stroma, an uncommon expression pattern for
normal hypoxic regulation (Figure 1, E and F).  
Discussion
Endothelial cell growth is an important mechanism for
processes of both tissue development and tumorigenesis.
While endothelial cells in general share many common
features, subsets of endothelial cells, in particular
endothelial cells of the glomerulus, express a unique
footprint of endothelial specific growth promoting genes
(19). Understanding mechanisms of disordered endothelial
cell growth, especially in unique locations such as the
kidney, is an important first step to unraveling the activities
of angiogenesis and vasculogenesis which play an important
part in the development of highly vascular tumors in the
kidney or other organs.
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Figure 1. Expression of hypoxic response targets in angiosarcoma. Immunohistochemistry detected diffuse strong staining with antibodies targeting (A)
VEGF, (B) VEGF-R2 (flk-1), (C) carbonic anhydrase, (D) erythropoietin, (E) HIF1·, (F) HIF2·. 20X resolution.
Taken together, our observations suggest that, in this
angiosarcoma, the hypoxic response pathway was aberrantly
activated as demonstrated by widespread high level
expression of both HIF1· and HIF2·. This mechanism for
the promotion of angiosarcoma is also supported by recent
studies of mouse models of tumorigenesis. In a mosaic
conditional knockout of VHL, the animals developed
angiosarcomas of the liver in addition to hemangiomas and
angiectasis in multiple tissues (20). Additionally, in the
TSC2+/- mouse, angiosarcomas developed on the tail, paws
and mouth (21). In this angiosarcoma, two autocrine
feedback mechanisms (both the VEGF and erythropoietin
signaling pathways), which could support tumor growth,
were activated in coordination with the HIF transcriptional
response pathway. While this correlation requires a more
thorough evaluation, it provides a unique potential pathway
for tumorigenesis which may provide targets for drug
therapy in this difficult to treat population.
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